The Novus Product Development Team is excited to announce the launch of a new antibody target not currently available by any other antibody suppliers. The two new antibodies, a human TMEM97 antibody (NBP1-30436) and mouse TMEM97 antibody (NBP1-30437) are of particular interest as TMEM97 is implicated in several cancers, including breast, pancreatic, colorectal and ovarian cancers. In an article published in Cell Metabolism this past July, TMEM97 was also identified as one of 20 genes that are functional regulators of cellular cholesterol homeostasis. Novus’ new human TMEM97 antibody has been successfully tested in both Western blot and immunocytochemistry. The mouse TMEM97 antibody is also useful for Western blot analysis and will be tested in immunocytochemistry within the next week.
In addition to this new product launch, the Novus antibody lab has also been busy with antibody conjugations. A few recently conjugated antibodies include BrdU antibody (NB500-235) to biotin and DyLight 488, Caveolin 1 antibody (NB110-74687) to Biotin, and Jumonji antibody (NB100-2214) to DyLight 649.
Novus’ laboratory technicians have also had their hands full with the QC testing of newly purified antibody lots. A new lot of LC3B antibody (NB600-1384) was tested in human brain lysate and achieved a specific band at 14kDa, consistent with previously purified lots of this antibody. The Tyro-3 antibody (NBP1-28635) was also QC tested on human brain lysate which produced a clear band at 96kDa. One of Novus’ embryonic stem cell markers, an anti-SOX2 antibody (NB110-37235), was also tested in Western blot. The SOX2 antibody was tested on mouse brain lysate where a strong signal at 39kDa was visualized.
The Novus antibody lab has also been busy with new antibody projects. A new autophagy-related antibody is currently in production; more details are expected to be released within the coming month. This new antibody complements Novus’ broad line of over 800 autophagy antibodies.